Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;14(3):218-26.
doi: 10.5811/westjem.2012.4.6885.

Oral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis

Jody L Green  1 , Kennon J Heard, Kate M Reynolds, Donald Albert
Affiliations

Oral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis

Jody L Green et al. West J Emerg Med. 2013 May.

Abstract

Introduction: There are few reports summarizing the effectiveness of oral and intravenous (IV) acetylcysteine. We determined the proportion of acetaminophen poisoned patients who develop hepatotoxicity (serum transaminase > 1000 IU/L) when treated with oral and IV acetylcysteine.

Methods: Studies were double abstracted by trained researchers. We determined the proportions of patients who developed hepatotoxicity for each route using a random effects model. Studies were further stratified by early and late treatment.

Results: We screened 4,416 abstracts; 16 articles, including 5,164 patients, were included in the meta-analysis. The overall rate of hepatotoxicity for the oral and IV routes were 12.6% and 13.2%, respectively. Treatment delays are associated with a higher rate of hepatotoxicity.

Conclusion: Studies report similar rates of hepatotoxicity for oral and IV acetylcysteine, but direct comparisons are lacking. While it is difficult to disentangle the effects of dose and duration from route, our findings suggest that the rates of hepatotoxicity are similar for oral and IV administration.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: By the WestJEM article submission agreement, all authors are required to disclose all affiliations, funding sources and financial or management relationships that could be perceived as potential sources of bias. This study was supported by Cumberland Pharmaceuticals (a manufacturer of IV acetylcysteine). All authors are employees of Denver Health. Denver Health has clinical, consulting and research contracts with Cumberland Pharmaceuticals (a manufacturer of IV acetylcysteine), Cadence Pharmaceuticals (a manufacturer of acetaminophen products) and McNeil Consumer Healthcare (a manufacturer of acetaminophen products). The investigators received only their salaries for work performed on this project. The sponsors had no role in the study design, performance, analysis or authorship of the article. The sponsor reviewed the final manuscript, but the authors are responsible for the final content. KH was also supported by Award Number K08DA020573 from the National Institute on Drug Abuse. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Drug Abuse or the National Institutes of Health.

Figures

Figure 1.
Figure 1.
PRISMA diagram of articles identified during the article search and abstraction process.
Figure 2.
Figure 2.
Forest plot showing proportion of patients with acetaminophen poisoning who developed hepatoxicity for intravenous and oral acetylcysteine treatment.
Figure 3.
Figure 3.
Forest plot showing proportion of patients with acetaminophen poisoning who developed hepatotoxicity for intravenous and oral acetylcysteine treatment when acetylcysteine was administered early (within 10 hours or as defined by author).
Figure 4.
Figure 4.
Forest plot showing proportion of patients with acetaminophen poisoning who developed hepatotoxicity for intravenous and oral acetylcysteine treatment when acetylcysteine was administered late (more than 10 hours or as defined by author).
See this image and copyright information in PMC

Comment in

References

    1. Manthripragada AD, Zhou EH, Budnitz DS. Characterization of acetaminophen overdose-related emergency department visits and hospitalizations in the United States. Pharmacoepidemiol Drug Saf. 2011;20(8):819–826. et al. - PubMed
    1. Prescott LF, Park J, Ballantyne A. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet. 1977;2(8035):432–434. et al. - PubMed
    1. Smilkstein MJ, Knapp GL, Kulig KW. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985) N Eng J Med. 1988;319(24):1557–1562. et al. - PubMed
    1. Bronstein AC, Spyker DA, Cantilena LR. 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clin Toxicol (Phila) 2010;48(10):979–1178. et al. - PubMed
    1. Brok J, Buckley N, Gluud C. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev. 2006;2006(2):CD003328. - PubMed